← Back to Search

Immunomodulator

Thymalfasin for Coronavirus (Ta1 Trial)

Phase 2

Waitlist Available

Led By Eleftherios Mylonakis, MD PhD FIDSA

Research Sponsored by Rhode Island Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 60

Awards & highlights

Ta1 Trial Summary

This trialwill test if a drug can improve COVID-19 recovery time & severity in hospitalized patients with low lymphocyte levels.

Eligible Conditions

Coronavirus

Ta1 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 60

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 60

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 60 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Time to recovery (free of respiratory failure)

Secondary outcome measures

AEs/SAEs

Change in any existing comorbidities (e.g., worsening congestive heart failure) or occurrence of newly diagnosed disease

Changes in laboratory parameters

+11 more

Ta1 Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Ta1 treatment armExperimental Treatment1 Intervention

Ta1 at a dose of 1.6 mg will be administered SC in 1 mL of diluent daily for a total of 1 week, in addition to standard of care.

Group II: Control armActive Control1 Intervention

No treatment will be provided in addition to standard of care.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Rhode Island HospitalLead Sponsor

260 Previous Clinical Trials

71,678 Total Patients Enrolled

Eleftherios Mylonakis, MD PhD FIDSAPrincipal InvestigatorLifespan

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open opportunities for recruitment into this research?

"The clinical trial is actively seeking volunteers, as evidenced on the website. It was initially posted to the platform on September 10th 2020 and has since been updated most recently on November 14th 2022."

Answered by AI

What therapeutic conditions does Thymalfasin typically help alleviate?

"Thymalfasin has been clinically tested to treat a variety of medical conditions, including adjuvant therapy, hepatitis b, chronic illness and vaccine-preventable diseases."

Answered by AI

How many participants are being considered for this research endeavor?

"Affirmative. According to clinicaltrials.gov, this medical trial is presently enrolling suitable candidates; it was initially posted on September 10th 2020 and has been updated most recently as of November 14th 2022. 80 individuals are needed to be recruited from a single site."

Answered by AI

What further research has been conducted with regards to Thymalfasin?

"At the current moment, 3 clinical trials are exploring Thymalfasin. One study is already in its final stage of testing and most research sites are situated in Kansas City, KS with a few other active locations around the country."

Answered by AI

Are there any substantial hazards associated with Thymalfasin?

"Thymalfasin is assessed to have a safety score of 2, due to the fact that it has undergone Phase 2 trials and thus there is some proof regarding its security but no evidence as yet demonstrating efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection

2020. "Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04487444.